CSL has agreed to acquire Vifor Pharma for US$179.25 per share which represents a total transaction value of US$11.7 B, a notable 40% premium over Vifor’s share price on December 1, 2021. The deal is in line with CSL’s attempt towards diversifying its portfolio beyond blood plasma. For Vifor, the deal comes just a month after it expanded its nephrology pipeline through the acquisition of Inositec and Sanifit Therapeutics, following disappointing results from a Phase III trial of ANG-3777.